secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001104659-24-006804
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance discloses FDA clinical hold on NSCLC TIL trial; BLA for lifileucel in melanoma under review
--------------------------------------------------------------------------------

- FDA placed clinical hold on IOV-LUN-202 trial (NSCLC) on Dec 22, 2023; new enrollment paused.
- BLA for lifileucel in advanced melanoma under FDA review with final label discussions ongoing.
- Presentation reports $428M cash as of 9/30/23 and 90%+ manufacturing success rate.
- Proleukin acquisition closed May 18, 2023 for £167.7M upfront; completed.
- Melanoma data: ORR 31.4% (pooled cohorts 2&4) with median DOR not reached at 36.5 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924006804/0001104659-24-006804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924006804/tm244175d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer